Standard Drug Discovery and Development

$1 to $2 billion

Cost of a new drug development

10 to 15 years

To develop a new drug

1:10k

Success rate

We can reduce those numbers to

$250k – $50M

Cost of a new drug development

4 to 5 years

To develop a new drug

3:10

Success rate

OUR APPROACH

Artificial Intelligence

Propietary Databases of Chemical Structures

Scientific Expertise

Learn about our Unique Approach

Our Directions of Work

Proprietary pipeline

Proprietary pipeline

PARTNERSHIP

Our performance indicators

12%

of our performed projects have
reached Clinical Phase 2

29%

of our projects have a positive
in vitro lead

We cooperate with

SOM Biotech in the media

LATEST NEWS

SOM Biotech at the BIO International Convention 2020
May 27, 2020

SOM Biotech will attend BIO International Convention 2020 in its virtual format “BIO Digital” on June 8th – 12th. The virtual gathering of the biotech industry will be one of the largest venues to be celebrated in 2020. It will allow companies to access key partners to explore opportunities and ...

Artificial Intelligence in Healthcare
The desperate use of drugs against coronavirus should be rationalized – Press release El PAÍS
May 12, 2020

SOM Biotech reoriented its capabilities to search for the treatments of COVID-19. Raúl Insa, CEO of SOM Biotech, acknowledges that he had never thought of using his technology to find treatment for infectious disease, but the situation is exceptional. “Our technology works based on chemical structure and we are looking ...

Artificial Intelligence in Healthcare
Artificial Intelligence in Healthcare Webinar
May 8, 2020

Interested in learning more about the role of Artificial Intelligence in Healthcare? Angelo Dalli, AI expert and serial tech entrepreneur, and Raúl Insa, CEO of SOM Biotech, will share their experience and thoughts on this topic at the webinar organized by EBAN – European Business Angels Network. The webinar will ...

We have positioned ourselves as a reference company in drug repositioning – Interview of Raúl Insa for “Actualidad Economica”
April 30, 2020

“Actualidad Economica” is the dean magazine of the Spanish economic press, founded in 1958. In the interview with the journal, Raúl tells about SOM Biotech creation, focus, and the objectives of the company. He describes the main development pipeline of SOM Biotech, and outline the expertise of its team. Raúl ...

SOM Biotech announces in vitro confirmation of three drug candidates for COVID-19 in collaboration with the Ewha Womans University
April 20, 2020

SOM Biotech announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replication of the virus. Clinical studies with the three candidates can be initiated immediately. SOM Biotech has applied its ...

SOM Biotech continues working during coronavirus outbreak to bring therapies for patients with rare diseases.
April 14, 2020

While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in ...

SOM Biotech strengthens its management team
April 8, 2020

SOM Biotech strengthens its management team with the appointment of Catherine Scart as Chief Medical Officer and Kevin McAllister as Chief Scientific Officer. Therefore, Catherine Scart MD will join SOM Biotech management team as Chief Medical Officer and will assume responsibility for the company´s clinical trials and lead the pipeline ...

SOM Biotech at the Eyeforpharma Barcelona Virtual
March 26, 2020

SOM Biotech will attend the Eyeforpharma Barcelona event that will be hosted online due to the impact of COVID-19, between March 31st and April 2nd 2020. Maria Zimina – Business Development Manager – underlines: “We look forward to having the opportunity to share and discuss with potential business partners and ...